Phensuximide
Milontin (phensuximide) is a small molecule pharmaceutical. Phensuximide was first approved as Milontin on 1982-01-01. It is used to treat absence epilepsy in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Phensuximide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| MILONTIN | Pfizer | N-008855 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| absence epilepsy | HP_0011147 | D004832 | G40.A |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
17 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | 1 | 1 | 7 | 3 | 12 |
| Acute coronary syndrome | D054058 | EFO_0005672 | — | — | — | 2 | — | 2 | |
| Coronary disease | D003327 | — | — | — | 1 | — | 1 | ||
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | — | 1 | — | 1 |
| Pulmonary embolism | D011655 | EFO_0003827 | I26 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | — | 1 | — | — | 1 |
| Venous thrombosis | D020246 | HP_0004936 | I82.40 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Thrombosis | D013927 | — | 2 | — | — | — | 2 | ||
| Hemorrhage | D006470 | MP_0001914 | R58 | — | 1 | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Venous thromboembolism | D054556 | EFO_0004286 | I74 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | PHENSUXIMIDE |
| INN | phensuximide |
| Description | Phensuximide is a member of pyrrolidines. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CN1C(=O)CC(c2ccccc2)C1=O |
Identifiers
| PDB | — |
| CAS-ID | 86-34-0 |
| RxCUI | 33309 |
| ChEMBL ID | CHEMBL797 |
| ChEBI ID | 8079 |
| PubChem CID | 6839 |
| DrugBank | DB00832 |
| UNII ID | 6WVL9C355G (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 119 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,538 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more